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Abstract In this work, we utilize a short-wavelength, 532-nm
picosecond pulsed laser coupled with a time-gated comple-
mentary metal-oxide semiconductor (CMOS) single-photon
avalanche diode (SPAD) detector to acquire Raman spectra
of several drugs of interest. With this approach, we are able
to reveal previously unseen Raman features and suppress the
fluorescence background of these drugs. Compared to tradi-
tional Raman setups, the present time-resolved technique has
two major improvements. First, it is possible to overcome the
strong fluorescence background that usually interferes with
the much weaker Raman spectra. Second, using the high pho-
ton energy excitation light source, we are able to generate a
stronger Raman signal compared to traditional instruments. In
addition, observations in the time domain can be performed,
thus enabling new capabilities in the field of Raman and
fluorescence spectroscopy. With this system, we demonstrate
for the first time the possibility of recording fluorescence-
suppressed Raman spectra of solid, amorphous and crystal-
line, and non-photoluminescent and photoluminescent drugs
such as caffeine, ranitidine hydrochloride, and indomethacin
(amorphous and crystalline forms). The raw data acquired by
utilizing only the picosecond pulsed laser and a CMOS SPAD
detector could be used for identifying the compounds directly
without any data processing. Moreover, to validate the accu-
racy of this time-resolved technique, we present density func-
tional theory (DFT) calculations for a widely used gastric acid
inhibitor, ranitidine hydrochloride. The obtained time-
resolved Raman peaks were identified based on the calcula-
tions and existing literature. Raman spectra using non-time-
resolved setups with continuous-wave 785- and 532-nm
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excitation lasers were used as reference data. Overall, this
demonstration of time-resolved Raman and fluorescence mea-
surements with a CMOS SPAD detector shows promise in
diverse areas, including fundamental chemical research, the
pharmaceutical setting, process analytical technology (PAT),
and the life sciences.
Keywords Raman . Time resolved . CMOSSPAD .
Pharmaceuticals . Fluorescence suppression . Process
analytical technology (PAT)
Introduction
Raman spectroscopy is beneficial for diverse types of quanti-
tative and qualitative analyses in fundamental chemical re-
search [1], life sciences [2, 3], and pharmaceutical research
and development, for example during dosage form
manufacturing, storage, and administration [4, 5]. Other dis-
ciplines include material analysis and mineralogy. However,
major limitations to its use have included photoluminescence
frequently masking the Raman signal [6], weak Raman scat-
tering, and insufficiently sensitive detectors. Some of these
problems have been resolved with improvements in hardware,
such as the development of efficient, low-noise, silicon-based
array detectors, stable high-power diode lasers, and high-
resolution spectrometers [7]. Thus, Raman has becomewidely
applied in both basic and applied chemistry. Despite the sig-
nificant technical advances, the weak signal and simulta-
neous ly s t rong ly in t e r f e r ing background f rom
photoluminescence are still hindrances in Raman spectrosco-
py. This is particularly problematic in the biomedical, life
science, and pharmaceutical settings where the analysis of
biological samples and drug molecules typically suffers from
strong photoluminescence backgrounds. At the same time,
there is an unquestionable need for label-free technologies
with sufficient temporal resolution for the detection of in situ
real-time phenomena. Such measurements include, for exam-
ple, phase transformation analysis of various drugs and exper-
iments with living cells [8].
The photoluminescence (PL) phenomena can be divided
into various types according to the specific molecular relaxa-
tion sequences that take place after the absorption of an inci-
dent photon [9]. However, fluorescence is usually the main
component of photoluminescence and also the one that over-
laps spectrally with the Raman spectrum, making it very dif-
ficult to remove from Raman measurements. Strong fluores-
cence is typically created in conjugated double bonds and
polycyclic aromatic rings, which are common structures in
many drugs and biological molecules. This fluorescence fre-
quently occurs on the same wavelength range as the Raman
fingerprint in a given experiment, and as fluorescence is usu-
ally a much stronger phenomenon, it can completely
overwhelm the Raman signal. The means to alleviate this
fluorescence problem in Raman spectrometry can be essen-
tially divided into continuous-wave (CW) and time-resolved
approaches. In addition, various algorithm-based methods re-
lying on the spectral post-processing have been introduced. In
order to clarify why these methods are typically used, several
statements related to photochemical and physical mechanisms
of photoluminescence phenomena are needed. Herein, we as-
sume that a laser with the center wavelength λL is used as the
excitation source. Firstly, the Raman phenomenon is an inelas-
tic scattering process present at all excitation wavelengths,
whereas fluorescence requires a nonzero electronic molecular
absorption coefficient at λL. The intensity of Raman scattering
is approximately proportional to 1
λ4L
. Thus, as a rule of thumb,
shorter wavelength lasers give rise to stronger Raman signal
intensities. Secondly, the spectral shape of fluorescence from a
collection of identical fluorophores is independent of λL while
the Raman spectrum as a whole is moved to shorter or longer
wavelengths along with the excitation. Thirdly, the temporary
storage of energy within the molecule after the absorption and
relaxation processes entails a characteristic statistical average
delay (having an exponential distribution with a certain expec-
tation value) before the emission of a fluorescence photon.
This is manifested as the fluorescence Btail^ after a short ex-
citation pulse. Theoretically, Raman scattering is an instanta-
neous process, and it does not involve such delays. However,
significant temporal broadening can be observed, which oc-
curs in thick scattering samples; it could be so that the analyte
molecules deeper in the sample will interact with the excita-
tion photons even hundreds of picoseconds later than the mol-
ecules on the surface [10, 11]. Methods to determine the decay
rate of Raman scattering have also been introduced [12]. It
turns out that the time dimension provides, in a sense, the most
general way to deal with fluorescence in Raman spectrometry.
In the following, the CW and time-resolved approaches are
briefly described.
In 1976, Funfschilling and Williams resolved the
fluorescence-related problems for the first time [13]. They
exploited the previously known method of phase sensitive
detection that had been effectively applied in nuclear magnetic
resonance (NMR), electron paramagnetic resonance (EPR),
and photoelectron spectroscopy. The common basis for those
methods was to shift the signals of interest away from the
interfering background. Thus, by modulating the Raman ex-
citation wavelength, the Raman signal could be recovered
from the overlapping fluorescence signal. Later on, a wave-
length differential technique was developed and became
known as shifted excitation Raman difference spectroscopy
(SERDS) [14]. To some extent, differential techniques are
applicable to separate fluorescence and Raman signals [15].
Noteworthy approaches include frequency and polarization
modulations. The advantage of these differential methods lies
in the possibility to separate the non-shifted continuous-
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wavelength (CW) fluorescence and Raman signals in a quan-
titative way. However, in general, these techniques have their
limitations, for example acquiring two separate spectra for
post-processing in order to resolve the Raman signals.
Since the Raman intensity is proportional to the fourth
power of the excitation laser’s frequency, the shorter wave-
length (i.e., higher frequency) lasers give rise to a stronger
Raman signal intensity. However, increasing the excitation
photon energy increases also the likelihood of a sample to
contain electronically excitable chromophores, each one of
which may contribute to fluorescence. Conversely, decreasing
photon energy decreases the number of such chromophores.
Using λL in the NIR range (typically 785–1064 nm) often
makes the fluorescence-to-Raman signal ratio decrease mark-
edly or even vanish. FTIR-Ramanmay be considered the gold
standard here. The downsides include the required detector
technology (e.g., InGaAs) having a high dark current, which,
combined with low Raman efficiency, leads to a reduced
signal-to-noise ratio (SNR) [16]. The required high laser pow-
ers can also lead to sample damage and destruction by heating.
Using λL in the UV range (<400 nm) has two advantages:
Raman efficiency is high and while fluorescence might be
present, it resides in the longer (VIS) wavelengths and thus
does not overlap with the Raman spectrum. However, the
phenomenon that UV excited Raman does not suffer from
fluorescence since it occurs in a different wavelength range
is only true for excitation wavelengths in the deep UV below
260 nm. The downsides include the generally increased diffi-
culty in making optics, lasers, detectors, and high-resolution
spectrographs for UV, along with the sample degradation due
to high photon energy compared to the VIS range [7]. Using
algorithms solely without any instrument-based means to sub-
tract the fluorescence background also has drawbacks. For
instance, even though the fluorescence profile of the measured
sample is relatively recognizable and smooth, a subtraction
algorithm produces only an estimate on fluorescence; relevant
spectra features may be subtracted, thus biasing the result.
Moreover, an additional problem with subtracting fluores-
cence is that the shot noise will remain. Finally, using
photobleaching as a means to exterminate the fluorescence-
generating chromophore groups of the molecules can be slow
and cause physical changes like burning to the samples. In
addition, photobleaching is not a suitable technique for living
organism- and cell-based assays.
Next, we consider the time-resolved approach to Raman
spectrometry. Several different types of time-gated Raman
systems has been demonstrated, among others those based
on an intensified charge-coupled device (ICCD) [17], a streak
camera, and an optical Kerr gate [18]. The ICCD can reach
<100 ps time gate width, and the full optical Kerr gate, com-
bined with a suitable laser, can reach time resolution of a few
picoseconds or better. The main drawbacks of these systems
compared to the current system based on a complementary
metal-oxide semiconductor (CMOS) single-photon avalanche
diode (SPAD) matrix and microchip laser are related to the
inherent complexity, bulkiness, and/or cost. Instead, the tech-
nology at hand in principle enables the development of robust,
compact, and affordable time-gated Raman spectrometers
with <100 ps time resolution. This follows from the facts that
the CMOS SPAD detector does not require extreme cooling
unlike scientific CCDs, and the laser technology is also poten-
tially compact. Therefore, this technology offers great promise
as practical instrumentation and replacement of CW Raman
systems not only in the field of pharmaceuticals but also in
general.
A schematic temporal shape of a Raman band with a PL
background is shown in Fig. 1. The curves represent schemat-
ically the time evolution of the Raman, PL, and total emission
intensity following an incident excitation pulse. The elastic
part (Rayleigh scattering and Fresnel reflection) has not been
depicted. As mentioned before, the Raman process differs
from the luminescence mechanisms with respect to the nature
and magnitude of the associated delays between photon inci-
dence and emission. The typical time scales for Raman are in
the sub-picosecond to picosecond range [12, 19], whereas
those of fluorescence (the fastest spontaneous PL process)
are in the 10-ps to 100-ns range [9]. Thus, if we take the laser
pulse width Δt=150 ps, the shape of the depicted Raman
pulse is very close to that of the excitation pulse apart from
a scaling factor. Using a fast photodetector such as a SPAD,
one can choose to record only the part of the emission pulse
containing the Raman pulse, in other words rejecting the PL
tail. Essentially, the associated photon noise is also rejected—
and this is the one fundamental advantage of a time-resolved
Raman measurement over any possible CW Raman measure-
ment, including differential techniques [20]. However, careful
inspection of Fig. 1 and the actual measurement data shows
that with our 150-ps excitation pulse, some luminescence is
emitted already during the pulse. This part of the PLwe hence-
forth call residual fluorescence (RFL). These issues will be
discussed in more detail later in this article.
In the present study, we demonstrate for the first time the
use of a novel detector system based on CMOS SPAD tech-
nology for the study of several pharmaceutical compounds.
Here, we utilize the power of combining a picosecond pulsed
laser with the time-resolved detection system to efficiently
reject the fluorescence and record detailed Raman spectra for
those compounds. Using a fast CMOS SPAD detector, we are
able to choose and to record only the part of the emission pulse
containing the Raman scattering by rejecting the fluorescence
tail. The drug molecule response is recorded during the short
laser pulses, and the CMOS SPAD detector is synchronized
with the laser pulse. However, typically, a part of fluorescence,
RFL, temporally overlaps the Raman signal and cannot be
rejected by time gating. To overcome the RFL, we present a
convenient algorithm to enhance the accuracy of acquired
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Raman spectra. We use a time-gated Raman to measure the
Raman spectra of four pharmaceutical compounds. These
were selected to include caffeine, as an easy reference com-
pound; ranitidine HCl as a previously less studied and difficult
compound; and indomethacin in both amorphous and crystal-
line forms, as particularly difficult ones suffering from strong
fluorescence issues. The capabilities of the new setup were
explored and compared to a conventional CW Raman
instrument.
Materials and methods
Materials The studied drugs were caffeine anhydrate (Orion
Pharma, Helsinki, Finland), ranitidine hydrochloride poly-
morphic form II (Hawkins Pharmaceutical Group,
Minnesota, USA), and indomethacin (crystalline γ-form,
Hangzhou Dayangchem, China). The molecular structures of
the studied compounds are presented in Table 1. Amorphous
indomethacin was prepared by heating the crystalline powder
in an aluminum dish for ∼15 min. All the other chemicals
were measured as received. In conventional Raman measure-
ments, the compounds were measured in sample holders with
the powdered drug layer height of approximately 2 cm. In the
time-resolved Raman measurements, a smaller amount of
drug (approximately 100–200 mg) was placed onto a sample
holder. The laser beam was directed onto the samples from
above with both setups.
Ramanmeasurements at 785 nm The Ramanmeasurements
at 785 nm were performed using a CW Raman RXN1-PhAT-
785-D-laser Invictus 785 nm (Kaiser Aerospace & Electronics
Company, USA). The probe was PhAT System Probehead
(Kaiser Optical Systems, Inc., USA), with collimated incident
radiation and a sampling diameter of approximately 6 mm.
The average laser power on the sample was ∼20 mW. The
detector was a charge-coupled device (CCD), 1024×256
EEC MPP Type (Kaiser Optical Systems, Inc., MI, USA)
cooled to −70 °C. The measurements were performed at am-
bient temperature and humidity, with dark background sub-
traction. Raman shift calibration was performed using cyclo-
hexane. The CW 785-nm Raman spectra presented in this
paper are an average of ten scans, each with an acquisition
time of 3 s and a spectral resolution of approximately 4 cm−1.
Raman measurements at 532 nm A continuous excitation
laser beam was focused down to a micrometer-sized spot on
standard substances through a confocal Ramanmicroscope. A
frequency doubled Nd:YAG, 532 nm linear polarized excita-
tion laser (∼20 mW) was used in combination with ×20
(Nikon, NA 0.40) and ×10 (Nikon, NA 0.25) microscope
objectives. The spectra were acquired using a CCD camera
(Andor Newton DU970-BV, Andor Technology plc, Belfast,
UK) behind a grating (600 g mm−1) spectrograph with a spec-
tral resolution of 2–3 cm−1. Integration times of the signal
were 0.5, 1, 2, and 5 s.
Time-gated picosecond Raman The time-resolved measure-
ments were performed using a laboratory setup with the fol-
lowing specifications: The excitation source was a custom-
made 532-nm Nd:YVO microchip pulsed laser. The average
power used was 14 mW, repetition rate 40 kHz, pulse width
150 ps, focus diameter 50 μm, pulse energy 0.35 μJ, peak
power 2 kW, and maximum irradiance 28 MW cm−2. To
Fig. 1 Schematic representation
of the laser excitation, Raman,
and photoluminescence signals
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alleviate photobleaching effects, the focal point was periodi-
cally moved over an area of about 1 mm2 by utilizing a
custom-made galvo-mirror arrangement. The spectrograph slit
was 50 μm, with ×1.7 magnification, 3.4 nm mm−1 disper-
sion, and about 13 cm−1 spectral resolution. The detector was
the 128×8 CMOS SPAD matrix detector developed by
Kostamovaara’s group in the University of Oulu. The detector
accumulates single-photon events in an internal time histo-
gram consisting of four bins. Only one of these bins was used
as the Btime gate^ in the data analysis presented below. The
instrument response function (IRF) is dominated by the laser
pulse shape, SPAD response shape, and time gate width of the
electronic width generator. The FWHM of the IRF, which is a
measure of the system’s time resolution, was approximately
250 ps. This approximation has been demonstrated earlier in
the literature [16]. The time-resolved spectral datasets were
collected by sequentially moving the gate in 50-ps steps using
the electronic delay generator. The data acquisition and setup
control was maintained by a digital microchip, field-
programmable gate array (FPGA). Data acquisition software
and setup control were carried out by in-house programs,
which were coded using LabVIEW (National Instruments
Corporation, TX, USA) language. The data was processed
and 3D graphics were plotted using Matlab (MathWorks,
MA, USA). The measurements were performed at ambient
temperature and humidity, and spectra were the sum of 1.2×
108–1.7×109 pulses corresponding to overall measurement
times in the range of 1–12 h. The signal level (counts/laser
pulses/pixel) was kept at the suitably low level of a few per-
cent at maximum to avoid signal distortion by photon
counting pile-up effects. It is to be noted that the acquisition
of a time-gated Raman spectrum alone, without the need to
collect the whole temporal shape using a 50-ps step size, can
be done in a fraction of the timementioned above, for instance
in the order of minutes or seconds. In future versions of the
hardware, larger detectors and adjustable laser repetition rates
enable bringing the measurement times to a level that is prac-
tical in even field and industrial process applications. The
schematic illustration of the Raman and fluorescence events
is presented in Fig. 1.
Residual fluorescence background subtraction The RFL
subtraction was performed by assuming that the fluorescence
is the only contributing factor in the Bvalleys^ of the time-
resolved Raman spectra. That signal can then be used to esti-
mate the contribution of fluorescence to the signal intensity in
the same time range as the Raman scattering (i.e., where the
Raman peaks occur). Unfortunately, the acquired Raman data
can be difficult to use for this, as the valleys are at varying
heights due to baseline shift and no simple control value can
be chosen. In order to get data to be internally comparable, the
whole Raman spectrum was first baseline corrected at each
Table 1 The chemical structures and physical characteristics of the studied compounds
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time step using a built-in function (msbackadj) of Matlab.
Next, a control value was chosen as the control valley area
where it was assumed that the signal is pure fluorescence with
no Raman scattering. For better representation of fluores-
cence, an average signal from three adjacent wavenumber bins
was used. The pure Raman spectra were obtained by eliminat-
ing the amount of fluorescence by subtracting the control val-
ley from the overall time-resolved response signal.
Fluorescence decay estimations The fluorescence decay es-
timations were performed assuming that the tested compounds
do not have multiple fluorescent components. Thus, a single-
exponential decay model, which fits well for gross estimations
performed herein, was chosen for the fluorescence decay es-
timations. Furthermore, the fluorescence decay estimations
were based on the assumption that there is only negligible
delay between photon absorption and the molecule’s relaxa-
tion to the lowest vibrational level in the first excited electron-
ic state before transitioning to the electronic ground state by
emitting a photon (fluorescence) and non-radiatively (internal
conversion) with the rate constants kF and knr, respectively.We
used a single-exponential decay model based on Eqs. (1) and
(2):
N tð Þ ¼ N0e− k Fþknrð Þt; ð1Þ
in which N0 is the population of excited molecules imme-
diately after a very short (delta function) laser pulse.
ΦF tð Þ ¼ k FN tð Þ; ð2Þ
in which ΦF is the instantaneous fluorescence intensity
(photons per unit time) at time t. The overall response function
of the instrument is essentially a convolution of the shape of
the laser pulse, the IRF, and the exponential decay shape that
is described by the characteristic photoluminescence behavior
of the sample. To perform the fluorescence decay time esti-
mations for the samples, single-exponential fitting was done
to the tail part of the collected data using Eqs. (1) and (2),
where applicable. Ideally, the influence of the laser pulse
and IRF would be differentiated from the exponential part.
However, instead of attempting a de-convolution process to
separate the exponential part from the effect of the laser pulse
and IRF, estimates of the prospective error were performed
with approximate simulations that are described in the
BDiscussion^ section.
Quantum chemical calculations Density functional theory
calculations were performed for vibrational mode assignment
of the ranitidine HCl spectra (modeled as ranitidineH+).
Molecular optimization and vibrational frequency calculations
were performed with Gaussian 09 [21] software using density
functional theory (DFT), and the B3-LYP functional with the
6-31G(d) basis set. The predicted vibrational modes were
scaled with the recommended factor of 0.9614 [22] using
GaussSum 2.2 [23] software and visualized using
GaussView (v. 5.0, Gaussian, Inc. Wallingford, CT, USA).
Results
CWRamanmeasurements at 785 and 532 nm The conven-
tional CW Raman spectra of the model drugs were measured
in the region 800–1800 cm−1. This spectral range encom-
passes the informative Raman features in both the fingerprint
and group frequency regions. The CW Raman spectra are
shown in Fig. 2A–H. In the Electronic Supplementary
Material (ESM) Tables S1–S4, the Raman peaks for every
drug are assigned between 800 and 1800 cm−1, based on the
quantum chemical calculations published previously or per-
formed in this study. In the tables, selected peaks are assigned
for CW non-time-resolved measurements and time-resolved
measurements. The spectra have been normalized from 0 to 1,
and in order to represent raw spectra, they have not been
smoothed.
Panels A and B of Fig. 2 show the Raman spectra of caf-
feine for CW 785-nm excitation source and CW 532-nm ex-
citation source, respectively. Very low fluorescence intensity
can be observed, and the Raman peaks can be easily recog-
nized. Panels C and D of Fig. 2 show the acquired CW 785-
and 532-nm Raman spectra for ranitidine hydrochloride. A
relatively large fluorescence background hampers the inter-
pretation of both, and only a handful of weak Raman peaks
really stand out. In Fig. 2E, F, for the crystalline form of
indomethacin, a fluorescence background is present, but ob-
servable Raman peaks can be separated with both setups.
Using the CW 785-nm excitation source for amorphous indo-
methacin, Fig. 2G, does not show any spectral details as fluo-
rescence dominates the whole spectrum. As observed in
Fig. 2H, the experiment with the CW 532-nm setup reveals
more interpretable spectral features.
On the basis of these CW measurements, all the samples
had undef ined background increase , ind ica t ing
photoluminescence, except for caffeine. Using the CW 785-
nm setup, the most fluorescent sample appears to be amor-
phous indomethacin, followed by ranitidine hydrochloride
and gamma crystalline indomethacin. However, with the
CW 532-nm instrument, the most fluorescent drug is
Fig. 2 The Raman spectra obtained using the CW 785-nm Raman
spectrometer for caffeine (A), the CW 532-nm Raman spectrometer for
caffeine (B), the CW 785-nm Raman spectrometer for ranitidine
hydrochloride (C), the CW 532-nm Raman spectrometer for ranitidine
hydrochloride (D), the CW 785-nm Raman spectrometer for crystalline
indomethacin (E), the CW 532-nm Raman spectrometer for crystalline
indomethacin (F), the CW 785-nm Raman spectrometer for amorphous
indomethacin (G), and the CW 532-nm Raman spectrometer for
amorphous indomethacin (H). All spectra are normalized from 0 to 1
b
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ranitidine hydrochloride, followed by amorphous indometha-
cin and then gamma crystalline indomethacin.
Time-resolved Raman measurements The time-resolved
spectra for the model drugs are represented in Fig. 3A–D. In
the panels, black lines correspond to acquired raw data, blue
spectra represent the baseline- and photoluminescence-
corrected data, and the 3D representations show the evolution
of the measured signal in time dimension. The measurement
region was 800–1800 cm−1. The time-resolved spectra
(Fig. 3A–D) were recorded separately for the regions 800–
1300 and 1300–1800 cm−1. The reason for this is related to
the length difference between the detector array and the spec-
trum produced by the spectrograph in the current setup. The
spectra have not been smoothed.
Figure 3A illustrates the time-resolved Raman spec-
trum for caffeine. Very little fluorescence is observed.
However, for ranitidine HCl and both forms of indo-
methacin (Fig. 3B–D), the fluorescence background is
substantially reduced, and more Raman details in the
spectra can be seen. As described earlier in this text,
the residual fluorescence (RFL) can be subtracted with
simple data manipulation. This is demonstrated below for
amorphous indomethacin as an example. Figure 4A, B
illustrates the acquired raw data. In the next step, the
baseline correction is performed, as shown in Fig. 4C,
D. A control valley at 1056 cm−1 was chosen as the
control area where it is assumed that the signal is pure
fluorescence with little or no Raman photons. As the
shape of the fluorescence does not change much in time,
the contribution of this control valley was subtracted
from the overall response signal, Fig. 4E, F. The method
was able to isolate the Raman peaks, as the 3D spectrum
is now homogenously flattened everywhere except the
Raman peak areas. In particular, the region between
950 and 1250 cm−1 becomes clear with this treatment
and four strong and sharp Raman peaks can be easily
seen. The estimated decay time for the control valley
was the same as the decay time estimated for the raw
data. Therefore, the spectral treatment was able to pre-
serve the shape of the fluorescence signal and to isolate
the fluorescence free time-resolved Raman response. In
summary, this straightforward data processing enhances
the interpretation possibilities even further, as the blue
spectra show in Fig. 3A–D.
With the present CMOS SPAD detector, three different
factors are simultaneously defined: the time distribution of
detected photons (Fig. 3A–D: the 3D panel representations;
time axis), the photon intensity (Fig. 3A–D: the 3D panel
representations; intensity axis), and the energies of photons
that arrive at the detector (Fig. 3A–D: the 3D panel repre-
sentations; wavenumber axis). Thus, an informative repre-
sentation of photon distribution is obtained as represented
in the panels. The 3D representations show the exact
starting point of the increase in Raman signal immediately
after the laser pulse, as well as the fluorescence rise and
decay. For example, in Fig. 3D for amorphous indometha-
cin, in the time domain, the maximum signal from Raman
scattering occurs shortly after the laser shot (yellow- and
red-colored peak regions). Moreover, the fluorescence ap-
pears to start dominating the response signal at ca. 2.5 ns
(blue, decaying slope). It is worth stressing that in the case
of relatively thick scattering samples, temporal broadening
of Raman signals may have contribution to the time at
which the fluorescence starts dominating the response sig-
nal [10, 11]. Importantly, this is a sample-specific phenom-
enon and depends on the sample’s fluorescence. The time-
domain analysis can be utilized to estimate the fluorescence
decay times, which we introduce in the BDiscussion^ sec-
tion. Another observation that can be made in the spectra
of Figs. 2 and 3 is that the shape of the fluorescence back-
ground is negative for the measurements recorded with CW
785-nm excitation, changing to a positive slope in the time-
resolved measurements. This effect can be attributed to the
different excitation wavelength and to the fact that the NIR
experiment is performed at the edge of the sensitivity curve
of the CCD detector.
Discussion
Fluorescence rejection with the pulsed picosecond laser
and the CMOS SPAD detector
The time-resolved setup used in this study has a 532-nm
pulsed laser, and it is combined with the CMOS SPAD
detector having relatively fast electronic gating possibility
to temporally resolve the Raman spectrum from the fluo-
rescence background. An example can be seen with the
amorphous form of indomethacin, which is yellow in col-
or. With the non-time-resolved CW 785-nm setup, it was
not possible to detect any Raman peaks due to the fluo-
rescence, and another CW 532-nm instrument had to be
used to acquire interpretable Raman spectrum. With the
time-resolved CMOS SPAD system, the analysis could
be conveniently done at once for all the model
Fig. 3 Time-resolved Raman spectra. Panels represent the 2D,
traditional Raman spectra (left) and the 3D spectra (right). The 2D plots
are reconstructed from two separate measurements after normalization of
the data. The vertical line separates the two measurements. The acquired,
unprocessed raw data is shown in the 3D plots to give a clear view of the
events in the time domain after the laser pulse; the initial rise of signal
after the laser pulse consists mainly of Raman scattering, and the settling
of the signal consists of the decaying fluorescence signal. The drugs
shown in the panels are A caffeine, B ranitidine hydrochloride, C
indomethacin (crystalline), and D indomethacin (amorphous)
b
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compounds. Furthermore, the other benefits of Raman
spectroscopy, such as minimal sample preparation, signifi-
cant amount of chemical information, and lack of sensitiv-
ity to sample water content, are preserved. Combined with
the fluorescence-suppressed Raman spectra, the time-
domain studies could be a useful tool in Raman spectros-
copy to evaluate various changes in a system such as
phase transitions or changes in the chemical content of
the medium in cell cultures. At the end of this discussion,
we preliminarily address the potential of exploiting the
time-dimension analysis parallel to the fluorescence-
suppressed Raman data. The effect of time resolution is
shown in Fig. 3; the spectra are shown as 2D and 3D
representations. The 2D spectra represent the spectrum
with the highest Raman scattering intensity collected after
the laser shot, i.e., it corresponds to one specific time
point in the 3D spectrum. This is close to the CW
Raman spectra in appearance (Fig. 2), and in terms of
signal-to-noise ratio, it is clearly better. On the other hand,
if one is interested in the Raman and fluorescence signals’
time evolution, the 3D data show the stack of spectra
from moments before the emission pulse, the rise of
Raman and fluorescence signals, and the decay of fluores-
cence. Further spectral treatments with simple algorithms
can be used to fully eliminate the contribution of residual
fluorescence (Fig. 3: BL- and PL-corrected data, Fig. 4)
from the time-resolved spectra. It is noteworthy that the
time-resolved raw spectra alone are able to show Raman
details on all the tested compounds. This makes the in-
strument potentially able to, for example, identify
Fig. 4 Acquired Raman data
from amorphous indomethacin
(A, B), baseline-corrected data
(C, D), and fluorescence-
subtracted data (E, F). Panels on
the left illustrate the intensity vs.
time measurements for each
wavenumber shown as a 3D
stack. Panels on the right are also
the top views
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compounds or different solid-state forms. However, in ac-
curate quantitative analysis, the algorithm-treated data can
be more useful.
Analysis of the measured drugs—new possibilities
with the time-resolved Raman
The Raman shifts for selected peaks from the CW 785-nm,
CW 532-nm, and the time-resolved spectra are shown in ESM
Tables S1–S4. For all crystalline samples, the band positions
are in close agreement. Raman band assignments have been
previously published using DFT calculations for caffeine and
crystalline and amorphous indomethacin, and these are also
included in ESM Tables S1, S3, and S4. Computational
chemistry-based band assignments have not previously been
published for ranitidine hydrochloride, and thus, density func-
tional theory calculations have been included in this study
(modeled as ranitidineH+) and prominent bands assigned in
ESM Table S2, together with their corresponding eigenvector
diagrams in ESM Fig. S2.
Although the thermodynamically stable crystalline forms
of drugs are most commonly used in solid dosage forms, dis-
ordered amorphous forms of poorly soluble drugs, such as
indomethacin, are of much interest to the pharmaceutical in-
dustry as a means to increase their apparent solubilities and
associated dissolution rates. The time-resolved setup is capa-
ble of revealing the fine structure of both forms, whereas with
the CW non-time-resolved instruments, obtaining Raman
spectra for both forms was more arduous. This is of utmost
importance in the pharmaceutical setting where discrimination
between crystalline and amorphous forms of substances is
required in order to determine phase transitions or ratios of
the two forms in a mixture. Moreover, as the time-resolved
setup was able to reveal even subtle Raman spectral features,
differentiation between solid-state forms of compounds can be
made with this novel Raman system. In the following section,
we discuss in more detail the band assignments for the model
drugs and describe in conceptual level some benefits that the
detailed Raman spectra can offer in pharmaceutical formula-
tion and processing contexts, as well as the novelty value of
these Raman measurements compared to traditional methods
and instruments.
Caffeine (1,3,7-trimethylpurine-2,6-dione) Caffeine is a
well-known central nervous system stimulant, found in many
dietary products and occasionally used to stimulate the cardiac
and bronchial systems. Caffeine is sensitive to polymor-
phism—and, from a pharmaceutical point of view, is an inter-
esting compound for closer examination due to the fact that
different polymorphs have potentially varying physicochemi-
cal properties as well as pharmacological activities [24]. For
caffeine, both experimental and computational Raman data
are well established; Fig. 2A, B; Fig. 3A; and ESM Table S1
show the measured Raman spectra and band assignments for
caffeine, respectively. In the present study, caffeine was cho-
sen to act as an easily measured reference drug. As expected,
spectra acquired byCWand time-resolved setups clearly show
the bands, and the peaks are in accordance between the instru-
ments and with the DFT-based calculated values that can be
found in the literature [24, 25]. The contributions from C–C,
C–N, C=N, and C=O bonds can be easily used in, e.g., che-
mometric analysis.
Ranitidine HCl (N-[2-[[[5-[(dimethylamino)methyl]-2-
furanyl]methyl]thio]ethyl]-N-methyl-2-nitro-l, l-
ethenediamine hydrochloride) Ranitidine HCl is a widely
used gastric acid inhibitor, acting as an H2 receptor antagonist.
Ranitidine HCl has two major polymorphs, form I and form II
[26]. Different solid-state forms or polymorphs of the same
compound exhibit different pharmaceutically important phys-
ical properties such as crystal habit (morphology), melting
point, and aqueous solubility. Therefore, identification and
characterization of the solid-state forms is important. In the
case of ranitidine HCl, form II exhibits favorable filtration and
drying characteristics over form I due to morphological differ-
ences, and this practical advantage was the basis for its much
disputed patent upon its serendipitous discovery by Glaxo
Group Ltd in 1981. Part of the patent disputes focused on
difficulties in analysis of the solid-state forms. Raman spec-
troscopy has since been shown to be a convenient technique
for this purpose [27]. Here, we present for the first time the
quantum chemical calculations to determine Raman peaks for
ranitidine HCl. On the basis of computational chemistry we
performed, the furan ring and CH2 (1170 cm
−1), the CH2
groups (asymmetric rock at 1254 cm−1 and wag 1301 cm−1),
furan (symmetric stretch at 1533 cm−1), and the CH2SCH2
group (symmetric wag at 1276 cm−1) contribute to the
Raman spectrum of ranitidine HCl. According to Fig. 2C, D;
Fig. 3B; and ESM Table S2, the CW 785-nm Raman system
has very limited capability to resolve interpretable peaks,
whereas the CW 532-nm and the time-resolved CMOS
SPAD instruments accomplish better to provide peaks that
are relatively well in line with the DFT calculated values.
However, these observations begin to show the limitations
of conventional CW Raman setups; one has to rely on
multiple-wavelength systems to measure various samples,
which is not often feasible or even possible. Interestingly,
the Raman peak at 1185 cm−1 has been evaluated to be char-
acteristic of ranitidine HCl polymorphic form II whereas the
peak at 1208 cm−1 would describe the existence of form I [28].
In Fig. 3B, 1186 and 1206 cm−1 exhibit shoulders of other
peaks, suggesting the existence of both polymorphic forms in
the sample. Furthermore, if the time-resolved representation
of the 2D spectrum, in Fig. 3B (black line showing the ac-
quired raw data), was chosen to be constructed from a slightly
different time point, the feature at 1186 cm−1 appeared more
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dominant (data not shown), and the signal was not swamped
by the otherwise strong fluorescent background, leading to the
hypothesis that form II was dominant in the sample. This
observation shows an important feature which is available
with the time-resolved CMOS SPAD technique. Namely, by
varying the time point (sampling point), from which the 2D
Raman spectrum is constructed, it is possible to utilize the
acquired raw data without further processing. A CW system
at 532 nm performed better over the CW785-nm system in the
case of ranitidine HCl, but in general, the apparent fluores-
cence rejection factor is very low, even with the time-resolved
Raman setup. It is worth stressing that the relatively low fluo-
rescence rejection factor might be due to a short lifetime fluo-
rescent impurity contribution that is difficult to sort out regard-
less of the system used. Nonetheless, compared to the conven-
tional CW systems, which have no possibility to examine the
spectra in the time dimension and at different time points after
the laser shot, the potential of this time-resolved technique
becomes clearer.
Indomethacin (crystalline) (2-[1-(4-chlorobenzoyl)-5-
methoxy-2-methylindol-3-yl] acetic acid) Indomethacin is
a non-steroidal anti-inflammatory drug. The crystalline γ-
form is the most stable form of indomethacin at room temper-
ature, and it exists as dimers in this solid-state form [29]. In the
present study, Fig. 2E, F; Fig. 3C; and ESMTable S3 show the
experimental and calculated data for crystalline indomethacin.
Variations between the measured and calculated values exist
for some peaks; however, the same trend can be observed in
an earlier study [30]. Nonetheless, the measured positions for
the peaks with the CW Raman systems and the time-resolved
setup match up relatively well, and the characteristic chloro-
benzene and indole ring contributions as well as oxygen and
nitrogen containing stretching vibrations are clearly observed
in the spectra.
Indomethacin (amorphous) For poorly water-soluble drugs,
the amorphous form has a significant advantage over the crys-
talline form, with a higher dissolution rate and apparent solu-
bility, but the downside is reduced stability during processing
and storage [31]. Thus, e.g., the manufacturing process in-
volving amorphous forms can be hard to control. Raman spec-
troscopy has proven to be the most sensitive method for the
investigation of various amorphous forms of indomethacin
when the forms have been studied with different techniques
and multivariate analysis [32]. However, a 1064-nm FT-
Raman accessory has been a prerequisite to acquire an inter-
pretable Raman spectrum without prior bleaching for amor-
phous indomethacin. Figure 2G, H; Fig. 3D; and ESM
Table S4 show the experimental and calculated data for amor-
phous indomethacin. Herein, with the 785-nm CW Raman
system, a useful Raman spectrum was practically impossible
to acquire. The CW experiment at 532-nm excitation gave
quite visible Raman peaks; however, the sample was not
chemically stable with 5-s integration times, leading to a dra-
matically raised baseline and subsequent saturation of the de-
tector due to photoluminescent degradation products. Thus,
the integration time of 2 s was chosen to be used with the
CW 532-nm setup.
When using the 532-nm excitation laser and time-resolved
detection, we are able to acquire a detailed Raman spectrum
for amorphous indomethacin. In an attempt to avoid the laser-
induced sample degradation, the galvo-mirror arrangement
was used to move the laser beam spot on the sample constant-
ly. Thus, we get the advantage of the short-wavelength exci-
tation source giving rise to higher Raman scattering intensities
while fluorescence is simultaneously efficiently suppressed by
the time-resolved technique. A similar inconsistency between
DFT calculated peak values and measured peak values is seen
as in the case of the crystalline form of indomethacin.
However, the spectra in Fig. 3C, D reveal detailed features
that can be conveniently utilized to investigate crystalline
and amorphous forms of indomethacin. For instance, the re-
gion between wavenumbers 1080–1450 cm−1 shows clear
shifts in peak intensities, shapes, and positions. Similar differ-
ences are also seen in the range of 1500–1700 cm−1.
The acquisition of accurate Raman spectra of both forms
can be performed with effective fluorescence suppression
without the need to switch between systems or perform exces-
sive data processing. Therefore, the time-resolved technique
presented here could open up new possibilities, e.g., in ana-
lyzing the phase transition processes in pharmaceutical set-
tings and investigating compounds that are known to be labo-
rious to measure with Raman instruments due to weak signals
and interfering fluorescence backgrounds.
Preliminary perspectives on the capabilities of the time-
dimension analysis The current time-gated measurement sys-
tem has two main capabilities: first, rejection of sufficiently
long-lived fluorescence or other background radiation from a
Raman signal, and on the other hand, measuring the spectrally
resolved fluorescence decay shape. We applied the previously
described single-exponential tail fitting to the studied samples.
Now, since caffeine does not have a fluorescence background
to speak of, and ranitidine HCl has very short fluorescence
lifetime, the only meaningful results are found in indometha-
cin. However, in the case of ranitidine HCl, even with the
time-resolving capacity in the present study being restricted
by the compound’s short fluorescence lifetime and thus the
setup’s time resolution, we were still able to make an estimate
of the fluorescence lifetime of ranitidine HCl. Namely, we
could tell whether the fluorescence lifetime was short or
long—a feature not available on conventional Raman setups.
The fitted, uncorrected lifetimes for indomethacin are about
2.1 ns for crystalline indomethacin and 2.3 ns for amorphous
indomethacin. According to a rough simulation model we
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performed, the actual, de-convolved lifetimes are approxi-
mately 100–200 ps shorter (data not shown). The exponential
fittings on the measured data are shown in ESM Fig. S1. The
capabilities of the system to measure general fluorescence
decay shapes (e.g., find parameters of multi-exponential de-
cays) will be expanded in the future. This involves determi-
nation of the instrument response function (IRF) in the sense
that its effects can be de-convolved. For measuring the actual
vibrational dynamics associated with the Raman processes
[12, 19], neither the time nor the wavelength resolution of
our system is sufficient. Nevertheless, in our current data,
one can detect certain ambiguities concerning the temporal
shapes of certain Raman peaks; these observations merit a
further study with higher temporal resolution in order to as-
certain their origin and significance.
Conclusion
We have shown the potential of fast, picosecond pulsed 532-
nm laser excitation coupled with a fast and sensitive CMOS
SPAD detector to overcome the known Achilles heel, fluores-
cence, in Raman spectroscopy. In addition, compared to the
conventional methods, we are potentially able to have more
detailed structural information on our sample molecules with
Raman spectroscopy by utilizing the efficiently fluorescence-
suppressed and accurate Raman spectra, and the time-domain
detection capability. The technical advantages of this CMOS
SPAD detector have been previously discussed elsewhere
[16]. Now, we demonstrate for the first time a step towards
applications with this time-resolved Raman system.We record
fluorescence-suppressed Raman spectra of solid, amorphous
and crys ta l l ine , and non-photo luminescent and
photoluminescent drugs such as caffeine, ranitidine hydro-
chloride, and indomethacin (amorphous and crystalline
forms). The raw data acquired by utilizing only the picosec-
ond pulsed laser and a CMOS SPAD detector proved useful
for identifying the compounds directly without any data pro-
cessing. Relatively straightforward algorithms can further di-
minish the fluorescence contribution in the acquired spectra,
showing potential for accurate quantitative analysis. In sum-
mary, our major findings were as follows. Firstly, by utilizing
the high photon energy 532-nm pulsed excitation source, we
are able to observe accurate Raman spectra features. The
quantum mechanical calculations for one of our model drugs,
ranitidine hydrochloride, the comparison to existing literature,
and experiments performed with CW 785- and 532-nm
Raman setups verified this. Secondly, we are able to diminish
the strong fluorescence backgrounds, especially on amor-
phous indomethacin. The findings with our model drugs indi-
cate the applicability of this time-resolved Raman technique to
overcome the ever-present problems of weak signal and fluo-
rescence in Raman spectroscopy—not only in pharmaceutical
settings but also in many other fields that would benefit from
the accurate chemical information Raman spectroscopy offers.
Several applications in the field of pharmaceutical industry
and bio- and life sciences would benefit from the time-
domain assays with Raman spectroscopy. For example, phase
transition processes, cellular uptake studies, and cell culture
studies regarding changes of the chemical concentrations in
the culture medium or nanoparticle uptake studies would be
potential areas for future research. Another potential option
for further studies would be an investigation of several drug
molecules in amorphous and crystalline solid-state forms. The
setup described is potentially a powerful and convenient tool
to overcome current fluorescence-related limitations of
Raman spectroscopy for laboratory and off-laboratory use,
while simultaneously providing complementary information
for Ramanmeasurements in the form of time-domain analysis.
The advantages of using this CMOS SPAD technique over the
existing instruments (for example [17, 18]) are practical and
robust operation of the system, compact size, and affordable
cost. In the case of varying samples in terms of fluorescence
interference, the CMOS SPAD setup can be feasibly used for a
range of samples without the need to change from one instru-
ment to another. Thus, it offers a very potential choice of
instrument for the field of Raman spectroscopy. Having
showed that this new Raman technique effectively suppresses
fluorescence, we envisage that it has also widespread applica-
tion in different pharmaceutical and biopharmaceutical con-
texts that have previously suffered from fluorescence
phenomena.
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